Making decisions in uncertain situations is part of daily life. New research from the University of Minnesota Medical School ...

On or about September 15, 2023, Neumora conducted the IPO and raised more than $250 million from the investing public. The lawsuit alleges that, unbeknownst to investors, Neumora's KOASTAL-1 study, ...

New research has uncovered that anxiety and apathy -- two common but distinct emotional states -- lead to fundamentally different patterns in how people learn and make decisions.

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Equities research analysts at Brookline Capital Management issued their Q2 2025 EPS estimates for shares of C4 Therapeutics ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...

That said, one stock that continues to stand out is Johnson & Johnson JNJ. The pharmaceutical giant's stock hit new 52-week highs of nearly $170 on Tuesday, with JNJ now up +16% year to date.

The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celtrion stated in a news release ...

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report)’s stock price was up 4.5% on Monday . The stock traded as high as $8.29 and last traded at $7.40. Approximately 277,078 shares traded hands ...

A high-fish diet is linked to less MS disability progression over time, which could be explained by high levels of omega 3 ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...